Funded Projects › FP7
MEDIA · The MEtabolic Road to DIAstolic Heart Failure
More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements contribute to DHF; 2) how diagnostic algorithms for DHF can be improved by assessing metabolic risk; 3) how correction of metabolic risk can open new therapeutic perspectives for DHF.Hereto MEDIA will: 1) Expose animal models of DHF to intense metabolic risk in order to accelerate DHF development. 2) Perform mechanistic studies in cardiomyocytes derived from DHF animal models or from DHF patients. Because of the acquired nature of metabolic risk, these studies will focus on posttranslational modifications of proteins and on epigenetic control of hypertrophy development. Their relevance for global LV function will also be appraised; 3) Perform mechanistic studies on myocardial collagen synthesis, which is enhanced by metabolic risk, and execute a phase II trial in DHF with cardiac specific antifibrotic therapy; 4) Explore the use of biomarkers as premorbid identifiers of DHF in existing cohorts of patients exposed to metabolic risk; 5) Prospectively test biomarkers and arterial stiffening, which is accelerated by metabolic risk, for their diagnostic potential in a large DHF cohort; 6) Assess myocardial metabolic substrate preference with modern imaging techniques and improve diastolic LV dysfunction through modified substrate utilization in a phase II trial.Expected results of MEDIA are: 1) Identification of metabolic risk-related mechanisms as therapeutic targets; 2) Improved diagnostic algorithms through inclusion of biomarkers and arterial stiffness tests. 3) Novel treatments consisting of modified myocardial substrate utilization and myocardial antifibrotic therapy.
Consortium · 22 organisations
STICHTING AMSTERDAM UMC
NL
UNIVERSITEIT ANTWERPEN
BE · €554,711
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
IE · €539,161
STICHTING VU
NL · €1,705,696
DIGNA BIOTECH, S.L
ES · €52,166
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
ES · €788,551
DEBRECENI EGYETEM
HU · €499,783
FONDATION TRANSPLANTATION
FR · €975,271
UNIVERSITEIT MAASTRICHT
NL · €1,053,750
UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO
IT · €532,472
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
NL
RUHR-UNIVERSITAET BOCHUM
DE · €916,945
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
DE · €772,260
OXI GEN LAB SRL
IT
UNIVERSITETET I OSLO
NO · €500,147
UNIVERSITATSKLINIKUM HEIDELBERG
DE · €127,800
UNIVERSIDADE DO PORTO
PT · €811,719
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
NL · €497,400
UNIVERSITA DEGLI STUDI DI PERUGIA
IT · €524,516
UNIVERSITA DEGLI STUDI DI BRESCIA
IT · €496,231
PLURI BIOTECH LTD
IL · €92,955
CARDIFF UNIVERSITY
UK · €530,187
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.